Importantly, this study did not find a link between GLP-1 medications and NAION.
A 2022 study published in JAMA Network Open found that people taking antidepressants experienced somewhat reduced weight loss with GLP-1 medications compared to those not taking antidepressants
Discussion In this study, the effects of Retatrutide on metabolic parameters and cognitive performance in diabetic and non-diabetic rats were evaluated from both physiological and behavioural perspectives in an insulindeficient, Streptozotocininduced diabetes model (present study)
Studies examining receptor binding have shown that Retatrutide demonstrates strong activity at the human GIP receptor while maintaining measurable activity at both GLP-1 and glucagon receptors, creating a balanced activation profile that allows researchers to explore receptor crosstalk and multi-pathway metabolic signaling [2]
Second, the sample size of the study was small
These treatments mimic the natural hormone GLP-1, helping regulate blood sugar, reduce appetite, slow digestion, and increase feelings of fullness